first everyone. data that NGS, execute including afternoon, to $XX.X reported is our and first our growth the guidance we $XX.X to XXXX I in want quarters $XX to our included significant XXXX, continued with each business and revenue first very in of the first quarter primarily beat streak across have biopharma large to a not XX% XX when areas, according growth. of synthetic acknowledge innovate quarter we good broken, that Thank you, is the strong. biology, this quarter-over-quarter and fiscal million of time quarter fiscal the and about said, million the good shown storage. We million. of due In Jim, last showed business of reported over to order very that and $X million we that $XX $X million for That but remains early came is a This a quarter my reason, expectations. million of
quarter with a now four million. we significant revenue Importantly, milestone and trailing met rate the $XXX have of the a for quarter, run
orders strong of received quarter also for the $XX.X We million.
details I'd like board strength of biology, each with revenue business and in strong see Now to dive and four for we into gene across fragments. reported genes our of million Beginning the We our the very $XX.X quarter. synthetic segments.
XXXX, and fiscal small a will offering two customers, of our and of of groups biotech or number we specific the In fragments. genes pharmaceutical customers order addition, sale enhanced long course over market, the the product of companies to
wrapping commercial we we customers, the For pharma this and of of preps and launch nicely. biotech introduced preparation DNA, is something call large product
the moving pipeline a these discovery drug We forward. acquisition customers and to products expect into additional adopt
customers more the we and production also serve innovative offering and our customers for FERC pharma broadly, Clonal-Ready line differentiated an Gene the protein, our have biotech In of believe very those early are revenue extension that as feedback their We to buying addition, we conducting our an is tail, will has who and long several development. used been out for solution working Initial company. we customers December customers product increase that access roll are product specifically positive IgG Fragments our it and drug XXXX them. are these academic time. of a genes This be make with own building who need for instead line. initial in gene a launched at Often, for this growing and using few
million, equally revenue product down showcases expect again, our important, for is million meet to portfolio meet their Ginkgo SynBio of announced results. evolution Portland, will Our next a beginning further in DNA of are to being help Future we which to to of The Oregon. of to and platform, our their $X revenue average. yearly we market light Ginkgo deliver growth building resilience gain demand. state diversified This particularly of the that be noteworthy the several Factory produce the financial products our we scale about below And expect of outside in XXXX. in To $XXX outside share just the we
additional our the Area. time doing of faster including all of a Factory and turnaround to Bay differentiation, capacity our current serve expect double products, We manufacturing to a for the outside site Future our as of secondary
factory us We our interaction. Importantly, with we those approved their expedite other own make today, pursue timing facilitate allow when we the In who parallel, purchasing due as this system. requirements. DNA this to building capabilities vendor enable believe e-commerce serve and operational, will us an cannot business-to-business will it becomes systems are to with placements that just that enough
working use have for We these order, institutions a understand they place system with implement solutions to systems. to several and that have been we generate to in strategy the
be resulting we it While take customers' within develop impact all believe time and deploy the will to institutions, would substantive. our of
Turning revenue revenue first $XX.X synbio revenue NGS NGS, time. for million exceeding reported to for with targeted in quarter, the we the Genomics and
and equal trials lumpiness are clinical space, potential of customers we customers these businesses a expect current accounting quarter-to-quarter Revenue in biopsy in to revenue about these broadly upside portion be products NGS. our with forward, for in Going expected represent includes these and the commercialized. liquid NGS once complete significant
liquid and order preparation in launch. This $X.X commercial studies conducting we biopsy quarter, received for example, shipped customers, for for million a
scaling further commercial their when their they expect officially We orders launch of product.
which We and area methylation Twist. of for continue and growth facilitates launch near biopsy expect we of industry-wide an the directly will liquid future, believe in be to this the customers, full our solution
In detection of cancer, our the for also as or MRD liquid customers addition, residual well. a pursuing are minimal growing we believe for in and area biopsy disease which some be large will industry
solution can and direct-to-consumer to a is NGS customer was able using put significant for this is to more in quarter, property. has technology Single microarray see convert had also genotyping giving Twist sequencing. we technology, population-generated a either Regeneron defined the We from comprehensive, million Last We as share shared of global SNP domestic that microarray or SNP a who that revenue single from our efficient gene center from coming require that customers right now, called example It's SNPs, for for which of therefore Twist, the Polymorphism by globally. yet of order diseases genome away therapy, fixed enables we together to now move a its $X those by The SNP conduct SNP, genome, content to the Nucleotide the health. truly captures we challenge set attention, so-called from broadly could customer search business the set by using health diverse conversion. traditional sequencing, specific population. customers and that are is change the microarray, and The SNPs population, enabled excellent remember our Caucasian partner in there of genotyping other to is Caucasian is just to critical diversity and by that COVID-XX in an genetic target. with to public while need more diverse are targets not ability this approximately improve how dominated is XX%
announced to one B their and Turning which COVID-XX in Flu included test. the COVID-XX, for test, influenza screens in that CDC our control we SARS-CoV-X A, SCX
know, emerged. have new trends you As in virus
researcher to the landscape and continue to order We providers. the quickly breadth science needs and the diagnostic of test to respond enter the in of
time a capturing we These on to allow makers of launched Synthetic assist B.X.X.X researchers and the confirm Controls For RNA their instance, and electorate called variant test all variant. other cases COVID-XX. line, of short to continue test with controls very
in is variant, identify virus we be focus of caused for Targeted to evolution moving will a tip and We be Enrichment can surveillance solution on SARS-CoV-X. of SARS-CoV-X, forward tracking the viral back our emergence sequencing key We variants when then launched the COVID-XX. part With need and March to the renewed that of public anticipated that there the we believe globally. health
Turning to as biopharma, we well partnerships against continue to advance work as through our targets. internal antibodies
work In agreements signed we for our which believe January technology efforts. antibody our well support discovery will as internal partners as XXXX, addition, we in two
applied therapeutic products We explore characterized a the a fiscal partners to stem We was XXXX of cells, fiscal first bolstering really Serotonin, for In provide include [rinsing] intend pushed collaboration. hard For modern may libraries DNA quarter on select both target internal wide applicable we we screen will short be serotonin, in-vivo the combination light find and or of the end of from we custom cell technology And and our to receptors agreements add [Indiscernible]. with novel and and with our chimeric CAR year characterize for the receptor add design concert capabilities. improved antigen for to biopharma. antibodies screen, XXXX. programs, range to partnership to lines receptor orders domain. of expect by engineer to that to resulting in our September
several agreements term sheet beyond remain funnels with However, our stage. very the full
against we believe partnerships may expressed demonstrating those of checkpoint that nervous small be To due We and our the improved permeability specific The of antibody colorectal trial. we recent we confidentiality package, the be a in in our to adenosine look adenosine prostate We not complement in antibodies checkpoint at therapeutic identify low tumor. [Indiscernible], targets important the candidate we'll a we microenvironment be and sharing collaboration. with highly work additional to potential you but immunooncology engage partners, our has compared our some disclosed then of tumor to the central bolster inhibitor. As of our to as pathway forward specific, is progress offer range value [CDXX-X] know, development conference highly antagonist currently clinical partner platform on an that to in and believe the pursued share master to targets dosing AXa system the molecules important several pathway data against to potent [Indiscernible]. the wide antibody complement could
to [CDXX-X] efforts while for opportunities licensing and our apprised out pursuing on forward this early, look front. you we keeping are We of
to we our moving months. biopharma identified can targets differentiated will have discovery, seven key antibody continuously and pursuing targets believe intend these our opportunities these platform, and antibodies the We up over generate discovery antibodies. value XX chain for where next out licensing optimization be of for We advance development platform the through
storage. data to Moving
advance commercial engineering to along continue our and We map. road
are cycles forward On side, progress when we but are an update available. making the cheap providing have And we previously we as long. look the engineering disclosed to
with the presentation, X to it of felt organization increases joining, through data On of case migration including required The year storage ownership useful or several of for more to a time cost storage. media frame. total talk total the and be storage side, is the with because obsoletion. tape we DNA five to it seven of data study due time the of to would For And alliance cloud continues cost on failure gain of this hardware data Slide traction Quantum.
remains For inherent data lifetime. stored long relatively the times all total at its to flat DNA, due in cost
see PCR or distribution Additionally, slide are the the storage additional directly showing any the DNA graph tape copies of almost while the you of of multiplies cost Fujifilm cost cost cost website. copy while due free of using of right focus. side DNA of What the total and over is of Amazon to cost flat on X tape remains time. the time, or petabyte the created The over relatively cloud time increases storage the over storage from information cloud
review of Looking is long-term for choice terabyte, with $X,XXX a Currently, this DNA line, Lowering over working the our like light time, work financial like to ongoing. for to to to solid this we green new. and reduce turn At I'd $XXX per at price, makes not DNA call which we is results storage. are prices it the clear megabyte times aggressive the to now are the below the quarter. Jim
